Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents.
Jones
Roy B
RB
Bone Marrow Transplant Program, University of Colorado Health Science Center, Denver, Colorado, USA.
D000478:Alkylation; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis; D004247:DNA / Q000378:metabolism; D004260:DNA Repair; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004259:DNA-Directed DNA Polymerase / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D005978:Glutathione / Q000378:metabolism; D005982:Glutathione Transferase / Q000378:metabolism; D006801:Humans; D008558:Melphalan / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*
D018906:Antineoplastic Agents, Alkylating; D004247:DNA; D005982:Glutathione Transferase; D004259:DNA-Directed DNA Polymerase; D004264:DNA Topoisomerases, Type I; D005978:Glutathione; D008558:Melphalan